Platform Trials to Expedite Drug Development in Alzheimer’s Disease: A Report from the EU/US CTAD Task Force

A diverse range of platforms has been established to increase the efficiency and speed of clinical trials for Alzheimer’s disease (AD). These platforms enable parallel assessment of multiple therapeutics, treatment regimens, or participant groups; use uniform protocols and outcome measures; and may...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of Prevention of Alzheimer's Disease 2021, Vol.8 (3), p.306-312
Hauptverfasser:	Aisen, P. S., Bateman, R. J., Carrillo, M., Doody, R., Johnson, K., Sims, J. R., Sperling, R., Vellas, B.
Format:	Artikel
Sprache:	eng
Schlagworte:	Advisory Committees Alzheimer Disease - drug therapy Alzheimer Disease - genetics Amyloid beta-Peptides Antibodies, Monoclonal, Humanized - therapeutic use Asymptomatic Diseases Biomarkers CTAD Task Force Paper Drug Development - standards Geriatrics/Gerontology Humans Life Sciences Medicine Medicine & Public Health Neurology Outcome Assessment, Health Care Research Design tau Proteins
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!